Discovers transformative small-molecule therapies for immune and inflammatory diseases using an AI-driven, physics-based chemistry platform to design novel molecules. Pipeline includes an oral STAT6 program with multiple novel scaffolds and an oral BRD4 (BD2) program with a first truly selective inhibitor; clinical trials expected in 2026.